Mindset Pharma (CSE: MSET) is to commence trading on the Canadian Securities Exchange (CSE) today (Wednesday, December 23rd).
Mindset Pharma is a drug and development company focused on creating new innovations in patentable psychedelic compounds for the treatment of neurological and psychiatric disorders. Mindset has been involved in assembling a proprietary library of psychedelic Intellectual Property (IP) designed to address chronic neuropsychiatric disorders efficiently and safely.
Capital 10X recently conducted an interview with Mindset’s CEO, James Lanthier:
James commented about the public listing:
“I am excited to share this announcement as it represents a significant milestone for Mindset and our shareholders. Our portfolio of next-generation patent-pending drug candidates and our innovative process to efficiently synthesize pharmaceutical-grade psilocybin are unique technologies that have the potential to play a significant role in the growth of the emerging psychedelic medication market.
With the proceeds from the closing of the Company’s recent private placement offering and the completion of Ontario Brain Institute investment, we are well funded to continue to advance and further develop our drug development and synthesis programs. We look forward to sharing additional updates around Mindset’s progress shortly.”
We will continue to track Mindset Pharma and the psychedelic industry and report on future developments.
The opinions provided in this article are those of the author and do not constitute investment advice. Readers should assume that the author and/or employees of Capital 10X hold positions in the company or companies mentioned in the article. For more information, please see our Content Disclaimer.